Volume 22 Issue 3
Mar.  2024
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2024  >  22(3): 428-432
SHEN Chen, LI Lisha, FU Jianying, XU Ping, LI Juan. Construction and application of standardized non-drug management scheme for progeny patients with degenerative diseases after liver transplantation[J]. Chinese Journal of General Practice, 2024, 22(3): 428-432. doi: 10.16766/j.cnki.issn.1674-4152.003418
Citation: SHEN Chen, LI Lisha, FU Jianying, XU Ping, LI Juan. Construction and application of standardized non-drug management scheme for progeny patients with degenerative diseases after liver transplantation[J]. Chinese Journal of General Practice, 2024, 22(3): 428-432. doi: 10.16766/j.cnki.issn.1674-4152.003418
shu

Construction and application of standardized non-drug management scheme for progeny patients with degenerative diseases after liver transplantation

doi: 10.16766/j.cnki.issn.1674-4152.003418

  • Department of Thyroid and Breast Surgery 2, Li Huili Hospital, Ningbo Medical Center, Ningbo, Zhejiang 315000, China

Funds:

 2023KY1031

 2022ZYC-A160

  • Received Date: 2023-11-08
    Available Online: 2024-05-27
    Abstract
  •   Objective  To establish standardized non-drug management scheme for progeny patients with degenerative diseases based on Delphi expert correspondence method, and analyze the practical effect.  Methods  Sixty-nine patients with progeny degenerative disease after liver transplantation treated in Li Huili Hospital of Ningbo Medical Center from May 2021 to March 2023 were selected as the study objects. According to different intervention methods, they were divided into the study group (34 cases) and the control group (35 cases). The study group received standardized non-drug management of progeny degenerative disease patients after liver transplantation, while the control group received routine nursing management. The blood glucose, blood pressure, blood uric acid, blood lipid and BMI levels of the two groups were compared before intervention and 3 and 6 months after intervention.  Results  The levels of fasting blood glucose, systolic blood pressure, diastolic blood pressure, blood uric acid, low density lipoprotein cholesterol, triglyceride, total cholesterol and BMI in both groups decreased gradually with the extension of time (P < 0.001), and there were interactions except BMI (P < 0.05). Regardless of time, 3 to 6 months after the intervention, the levels of fasting blood glucose[(7.20±1.23) mmol/L vs. (7.92±1.56) mmol/L, (6.82±1.09) mmol/L vs. (7.51±1.35) mmol/L, t=2.125, 2.332, P=0.037, 0.023], systolic blood pressure, diastolic blood pressure, blood uric acid, low density lipoprotein cholesterol, triglyceride, total cholesterol and BMI in the study group were lower than those in the control group (P < 0.05).  Conclusion  The establishment of a standardized non-drug management program for patients with degenerative diseases after liver transplantation, which guides patients to eat a healthy diet, exercise reasonably, change their bad habits, and enhance their mental health status, is conducive to the correction of metabolic disorders.

     

    • FullText(HTML)
  • loading
    • References(20)
  • [1]
    GITTO S, FALCINI M, MARRA F. Metabolic disorders after liver transplantation[J]. Metab Syndr Relat Disord, 2021, 19(2): 65-69. doi: 10.1089/met.2020.0068
    [2]
    HESSHEIMER A J, RIQUELME F, FUNDORA-SUAREZ Y, et al. Normothermic perfusion and outcomes after liver transplantation[J]. Transplant Rev (Orlando), 2019, 33(4): 200-208. doi: 10.1016/j.trre.2019.06.001
    [3]
    叶少炜, 钱均霖, 胡泽民. 肝移植后代谢综合征及其防治的研究进展[J]. 岭南现代临床外科, 2022, 22(2): 199-204. doi: 10.3969/j.issn.1009-976X.2022.02.016
    [4]
    QU W, WEI L, ZHU Z J, et al. Considerations for use of domino cross-auxiliary liver transplantation in metabolic liver diseases: a review of case studies[J]. Transplantation, 2019, 103(9): 1916-1920. doi: 10.1097/TP.0000000000002602
    [5]
    KOK B, DONG V, KARVELLAS C J. Graft dysfunction and management in liver transplantation[J]. Crit Care Clin, 2019, 35(1): 117-133. doi: 10.1016/j.ccc.2018.08.002
    [6]
    中国医药生物技术协会慢病管理分会. 肝硬化合并糖尿病患者血糖管理专家共识[J]. 中华糖尿病杂志, 2022, 14(8): 749-763. doi: 10.3760/cma.j.cn115791-20220624-00291
    [7]
    高血压患者药物治疗管理路径编写委员会. 高血压患者药物治疗管理路径专家共识[J]. 临床药物治疗杂志, 2022, 20(1): 1-24. doi: 10.3969/j.issn.1672-3384.2022.01.001
    [8]
    中国医师协会器官移植医师分会, 中华医学会器官移植学分会肝移植学组. 中国肝移植受者代谢病管理专家共识(2019版)[J]. 器官移植, 2020, 11(1): 19-29. https://www.cnki.com.cn/Article/CJFDTOTAL-QGYZ202001004.htm
    [9]
    沃琪, 任咪, 张金彦, 等. 肥胖与肝病: 肝移植的新时代[J]. 肝脏, 2019, 24(11): 1227-1228. doi: 10.3969/j.issn.1008-1704.2019.11.005
    [10]
    LONARUDO A, MANTOVANI A, PETTA S, et al. Metabolic mechanisms for and treatment of NAFLD or NASH occurring after liver transplantation[J]. Nat Rev Endocrinol, 2022, 18(10): 638-650. doi: 10.1038/s41574-022-00711-5
    [11]
    PFLUGRAD H, NÖSEL P, DING X, et al. Brain function and metabolism in patients with long-term tacrolimus therapy after kidney transplantation in comparison to patients after liver transplantation[J]. PLoS One, 2020, 15(3): e0229759. DOI: 10.1371/journal.pone.0229759.
    [12]
    SANADA Y, SAKUMA Y, ONISHII Y, et al. Outcomes after living donor liver transplantation in pediatric patients with inherited metabolic diseases[J]. Ann Transplant, 2021, 26: e932994. DOI: 10.12659/AOT.932994.
    [13]
    WANG Y J, LI J H, GUAN Y, et al. Diabetes mellitus is a risk factor of acute kidney injury in liver transplantation patients[J]. Hepatobiliary Pancreat Dis Int, 2021, 20(3): 215-221. doi: 10.1016/j.hbpd.2021.02.006
    [14]
    VAN SON J, STAM S P, GOMES-NETO A W, et al. Post-transplant obesity impacts long-term survival after liver transplantation[J]. Metabolism, 2020, 106: 154204. DOI: 10.1016/j.metabol.2020.154204.
    [15]
    CZARNECKA K, CZARNECKA P, TRONINA O, et al. Multidirectional facets of obesity management in the metabolic syndrome population after liver transplantation[J]. Immun Inflamm Dis, 2022, 10(1): 3-21. doi: 10.1002/iid3.538
    [16]
    杨倩, 陈玲, 李亚玲, 等. 肝移植术后代谢综合征预防与管理的证据总结[J]. 中华现代护理杂志, 2022, 28(18): 2424-2430. doi: 10.3760/cma.j.cn115682-20211011-04589
    [17]
    中国医师协会器官移植医师分会移植免疫学专业委员会, 中国康复医学会器官移植康复专业委员会, 广东省医师协会器官移植医师分会. 慢加急性肝衰竭肝移植围手术期康复评估与干预专家共识[J]. 器官移植, 2022, 13(5): 543-554. doi: 10.3969/j.issn.1674-7445.2022.05.001
    [18]
    SAKAI T, K0 J S, CROUCH C E, et al. Perioperative management of adult living donor liver transplantation: Part 1 - recipients[J]. Clin Transplant, 2022, 36(6): e14667. DOI: 10.1111/ctr.14667.
    [19]
    庄莉, 刘相艳. 肝移植受者围手术期管理及并发症预防与治疗[J]. 中华消化外科杂志, 2021, 20(10): 1037-1041. doi: 10.3760/cma.j.cn115610-20210915-00459
    [20]
    王宇航, 沈振亚. 脂代谢对主动脉疾病发生发展及预后的影响[J]. 中华全科医学, 2023, 21(8): 1374-1378. doi: 10.16766/j.cnki.issn.1674-4152.003126
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (46) PDF downloads(0) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return